TP53 and myelodysplastic syndrome: To this end, Saft and colleagues (44) recently reported a retrospective study of the prognostic significance of cellular p53 expression detected by immunohistochemical staining and TP53 gene mutation in a series of IPSS low or int-1 risk del(5q) MDS patients treated with lenalidomide in the MDS-004 trial (44, 45).